Home » Stocks » PCRX

Pacira Biosciences, Inc. (PCRX)

Stock Price: $73.50 USD -0.95 (-1.28%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 3.26B
Revenue (ttm) 421.10M
Net Income (ttm) 126.12M
Shares Out 42.93M
EPS (ttm) 3.33
PE Ratio 22.07
Forward PE 18.98
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $73.50
Previous Close $74.45
Change ($) -0.95
Change (%) -1.28%
Day's Open 75.05
Day's Range 71.89 - 75.74
Day's Volume 501,739
52-Week Range 27.46 - 80.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 22 hours ago

Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.

Zacks Investment Research - 1 day ago

Pacira (PCRX) delivered earnings and revenue surprises of 6.10% and -0.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 days ago

— Reports record full-year 2020 revenue of $429.6 million  —

GlobeNewsWire - 1 week ago

PARSIPPANY, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial res...

24/7 Wall Street - 2 weeks ago

With the trading day more than halfway over, the broad markets were trading sideways on Thursday.

Other stocks mentioned: CSCO, LYFT, UBER, VMW, CCJ, IRBT, MELI, PACB, SUMO
GlobeNewsWire - 2 weeks ago

EXPAREL average daily sales at 108% of the prior year for the month of January 2021 EXPAREL average daily sales at 108% of the prior year for the month of January 2021

GlobeNewsWire - 1 month ago

Supports Development of Promising Gene Therapy Platform for Osteoarthritis Supports Development of Promising Gene Therapy Platform for Osteoarthritis

Zacks Investment Research - 1 month ago

AMRX vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: AMRX
GlobeNewsWire - 1 month ago

-- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December -- PARSIPPANY, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Paci...

GlobeNewsWire - 1 month ago

PARSIPPANY, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 7:30 A...

GlobeNewsWire - 2 months ago

-- EXPAREL average daily sales at 103% of the prior year for the month of November 2020 -- PARSIPPANY, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the lead...

GlobeNewsWire - 3 months ago

PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Confe...

Zacks Investment Research - 3 months ago

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in ...

GlobeNewsWire - 3 months ago

--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachia...

GlobeNewsWire - 3 months ago

-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- -- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 --

GlobeNewsWire - 3 months ago

PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at ...

Zacks Investment Research - 3 months ago

Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.

Seeking Alpha - 3 months ago

Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET --

Zacks Investment Research - 4 months ago

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

--The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- PARSIPPANY, N.J., and TAMPA, Fla., Oct. 21, 2020 (GLOBE NEWSWIR...

Zacks Investment Research - 4 months ago

Pacira BioSciences (PCRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 4 months ago

PARSIPPANY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. m...

Zacks Investment Research - 4 months ago

Is (PCRX) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 4 months ago

-- EXPAREL average daily sales at 110% of the prior year for the third quarter and 110% of the prior year for the month of September -- PARSIPPANY, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Paci...

Zacks Investment Research - 5 months ago

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

GlobeNewsWire - 5 months ago

-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Appli...

GlobeNewsWire - 5 months ago

ALPHARETTA, Ga. and PARSIPPANY, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX)...

GlobeNewsWire - 5 months ago

PARSIPPANY, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment ...

GlobeNewsWire - 5 months ago

-- EXPAREL average daily sales at 111% of the prior year for the month of August 2020 -- PARSIPPANY, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a lead...

Zacks Investment Research - 5 months ago

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 6 months ago

Pacira BioSciences's (PCRX) CEO David Stack on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

Zacks Investment Research - 6 months ago

Pacira (PCRX) delivered earnings and revenue surprises of -25.00% and -0.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Paci...

GlobeNewsWire - 6 months ago

PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference a...

GlobeNewsWire - 6 months ago

– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –

GlobeNewsWire - 6 months ago

sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over

GlobeNewsWire - 6 months ago

PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S...

Zacks Investment Research - 6 months ago

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GlobeNewsWire - 6 months ago

Pacira to Pay $3.5 Million to Settle Various Claims with No Admission of Wrongdoing Pacira to Pay $3.5 Million to Settle Various Claims with No Admission of Wrongdoing

Zacks Investment Research - 7 months ago

Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for July 21st

Other stocks mentioned: EBS, TSM, USNA
Zacks Investment Research - 7 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: AMRC, CSIQ, EBS, NLS
Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for July 10th

Other stocks mentioned: BSIG, NLS, UMRX
GlobeNewsWire - 7 months ago

PARSIPPANY, N.J., July 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior not...

Zacks Investment Research - 7 months ago

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic.

Zacks Investment Research - 7 months ago

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Other stocks mentioned: ALPN, ATNM, TBIO
GlobeNewsWire - 7 months ago

PARSIPPANY, N.J., July 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $300.0 million a...

About PCRX

Pacira BioSciences provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold tempera... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 3, 2011
CEO
David M. Stack
Employees
606
Stock Exchange
NASDAQ
Ticker Symbol
PCRX
Full Company Profile

Financial Performance

In 2019, PCRX's revenue was $421.03 million, an increase of 24.83% compared to the previous year's $337.28 million. Losses were -$11.02 million, 2,238.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is 73.57, which is an increase of 0.10% from the latest price.

Price Target
$73.57
(0.10% upside)
Analyst Consensus: Buy